- Home
- PLG vs PRLD Comparison
PLG vs PRLD Comparison
Compare PLG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | PRLD |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 207.5M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLG | PRLD |
|---|---|---|
| Price | $1.82 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | ★ 2.1M | 305.5K |
| Earning Date | 04-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $0.99 | $0.61 |
| 52 Week High | $4.04 | $4.19 |
Technical Indicators
Market Signals| Indicator | PLG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 54.67 |
| Support Level | $1.39 | $1.02 |
| Resistance Level | $1.89 | $4.10 |
| Average True Range (ATR) | 0.15 | 0.33 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 2.03 | 41.78 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.